Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: Headache; Dyspnoea; Numbness of limbs; Tachypnea; Hyperventilation syndrome; mental tension; This is a spontaneous report from a contactable physician received from the Regulatory Authority. Regulatory authority report number is v21112221. The patient was an 18-year and 8-month-old female. Body temperature before vaccination was 36.9 degrees Centigrade (on 03Jun2021). The patient had no medical history. On 03Jun2021 at 15:00 (the day of vaccination) (18-year-old at vaccination), the patient received the first dose of BNT162B2 (COMIRNATY, solution for injection, lot number FA2453, expiration date 31Aug2021) via an unspecified route of administration as a single dose for COVID-19 immunization. Concomitant medications were not reported. On 03Jun2021 at 15:08 (8 minutes after the vaccination), the patient experienced headache, dyspnoea, and numbness of limbs. On 03Jun2021 (the same day of the vaccination), the outcome of the event was recovered. The course of the event was as follows: About eight minutes after the vaccination, the patient experienced headache, dyspnoea, and numbness of limbs. Oxygen administration, adrenaline 0.3mg intramuscular, securing vascular access was carried out. The patient was experiencing tachypnea. Auscultation was performed but no wheeze was observed. With the Breathing rate became normal, headache and numbness of limbs disappeared. About two hours later, symptoms totally disappeared. There was absolutely no blood pressure low and oxygen saturation low during observation. The reporting physician classified the event as non-serious and assessed that the causality between the event and BNT162B2 as unassessable. Other possible cause(s) of the event such as any other diseases was Hyperventilation syndrome. The reporting physician commented as follows: Judged by symptoms happened during observation, the physician guessed that hyperventilation syndrome was caused by mental tension. The physician thought that no anaphylaxis, no adrenaline administration was needed (as reported). The outcome of all events was resolved on 03Jun2021 at 17:08.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166